Navigation Links
AlphaRx and Gaia BioPharma Provide GAI-122 Development Update
Date:6/16/2009

    GAI-122, an investigational injectable nano-emulsion formulated with
    AlphaRx's proprietary drug delivery technology, provides significant
    neuroprotection in animal behavioral models. Gaia BioPharma plans to
    initiate a clinical development program to further study GAI-122 for an
    acute and as yet, unmet neurological indication.

MARKHAM, ON, June 16 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTCBB: ALRX) and Gaia BioPharma Limited, a privately held, early stage biopharmaceutical company focused on hospital-based injectable therapeutics, are pleased to provide a progress report on GAI-122.

GAI-122 offers significant and direct neuroprotection in both in vitro and in vivo ischemic conditions. Experimental evidence suggests that the neuroprotective action of GAI-122 is related to its' active inhibition of apoptosis or cell death. GAI-122 shows potential as a major treatment innovation in the management of ischemic neurological disorders such as stroke and traumatic brain injury.

The proposed initial indication for GAI-122 is an acute neurological disorder affecting millions of patients undergoing cardiac and hip replacement surgery. It is estimated that the market potential for this unmet indication exceeds US$2 billion a year.

GAI-122 is in the final stage of formulation optimization, which is expected to be completed by the end of summer 2009, proceeding to clinical trial materials manufacturing thereafter. GAI-122 is protected by 4 US patent applications.

In October 2008, AlphaRx licensed GAI-122 to Gaia BioPharma. Under the terms of the amended agreement, AlphaRx is eligible to receive milestone payments of up to $50 million for the successful development and commercialization of GAI-122, as well as royalties on worldwide sales. In addition, Gaia BioPharma has assumed all development costs.

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development.

About Gaia BioPharma

Gaia BioPharma Limited, a privately held, early stage biopharmaceutical company focused on hospital-based injectable therapeutics. Gaia BioPharma seeks to address key unmet therapeutic needs by taking established compounds and changing their administration routes to create patent-protected, value-added products.

FORWARD LOOKING STATEMENTS:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.


'/>"/>
SOURCE AlphaRx Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AlphaRx Signs Cooperative Research and Development Agreement with US Army
2. AlphaRx Provides Corporate and Development Update
3. AlphaRxs Indaflex(TM) Continues its Clinical Development
4. AlphaRx CEO Accumulates More Company Shares
5. AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares
6. AlphaRx Announces Debt Conversion
7. AlphaRx To Present at 47th Annual ICAAC
8. PDL BioPharma Announces Record Date for October 1 Dividend Payment
9. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
10. SAFE-BioPharma Webinar Featuring ARX's Digital Signatures Combined with Microsoft SharePoint for Bio-Pharma industry
11. Prix Galien USA Now Accepting Nominations for Premiere Biopharmaceutical Industry Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... 2017 , ... An August 3rd article on Reuters covers a new University of ... JAMA (the Journal of the American Medical Association). The study found that a lower percentage ... 30, when compared to patients with lower BMIs. At present, weight loss patients must have ...
(Date:8/16/2017)... ... August 16, 2017 , ... The Data Council, the leading ... was acquired by Advantage Solutions. The Data Council’s IX-ONE platform is the ... industry’s leading suppliers, brokers, distributors and retailers. The Data Council will become a ...
(Date:8/16/2017)... ... August 16, 2017 , ... In ... They celebrate 30 years in business this year, and they’re marking the milestone ... space to serve their patients. , It stands to reason that, given ...
(Date:8/16/2017)... ... August 16, 2017 , ... Modern Consulting Insurance & ... program. Partnering once again with Boys & Girls Clubs of Greater Kansas City, ... area’s very own American Idol. With all proceeds benefitting local worthy causes, donations ...
(Date:8/16/2017)... ... ... Paul Vitenas, MD, FACS , is honored to announce that he ... the nation’s top physicians, in a variety of specialties. This marks the fourth year ... Connolly’s coveted ranking. , Castle Connolly is the nation’s trusted provider of information on ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... , Aug. 2, 2017 ... Who,s Who as a Pinnacle Lifetime Professional in ... Key Account Manager at Turing Pharmaceuticals, AG. Her ... troubleshooting and relationship building.                ... more than 25 years of experience as a ...
(Date:8/1/2017)... 2017   CerSci Therapeutics , a non-opioid drug ... , has received notice from the National Institute on ... (NIH) that it has been awarded a Direct-to-Phase II ... in 2017 with an additional $1,000,000 to follow in ... application of their lead non-opioid drug candidate CT-044 to ...
(Date:7/28/2017)... July 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") ... third quarter ended June 30, 2017, and updated its ... For the fiscal third quarter, Hill-Rom ... $0.68 per diluted share in the prior-year period. These ... $0.39 per diluted share primarily related to the non-cash ...
Breaking Medicine Technology: